Why These 15 Healthcare Stocks Are Surging in 2025

Page 13 of 14

2. X4 Pharmaceuticals Inc (NASDAQ:XFOR)

Number of Hedge Fund Holders In Q4 2024: 8

X4 Pharmaceuticals Inc (NASDAQ:XFOR) is a clinical-stage biopharmaceutical company developing novel therapies that improve immune cell trafficking, with a focus on rare diseases such as WHIM syndrome and chronic neutropenic disorders.

The stock is up significantly so far in 2025 as the company’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist that received U.S. approval in 2024 and is now being marketed for WHIM syndrome.

This marked X4’s transition to a fully integrated commercial company. The most impactful event for the stock in 2025 has been the continued commercial rollout of XOLREMDI, the initiation and expansion of the global Phase 3 4WARD trial for chronic neutropenia, and the anticipation of potential European approval.

On April 24, 2025, X4 announced a reverse stock split to address Nasdaq’s minimum bid price requirement, which is intended to stabilize and potentially boost the share price. The company reported $2.6 million in net revenues from XOLREMDI since its May 2024 launch and expects a significant ramp-up in 2025 as physician outreach increases. The stock has since experienced high volatility.

The consensus price target of $85 implies significant upside from the current price.

XFOR stock is up 676.99% year-to-date.

Page 13 of 14